• Tianda Pharmaceuticals posted a net loss of HK$32.22 million, narrowing from HK$33.5 million a year earlier; loss per share improved to 1.5 HK cents.
• Revenue rose 20.19% to HK$164.22 million, while gross profit climbed to HK$66.14 million and gross margin slipped 1.1 percentage points to 40.3%.
• Loss before tax narrowed to HK$31.24 million as selling and distribution expenses increased to HK$54 million and administrative expenses rose to HK$39.13 million.
• Pharmaceuticals and medical technologies revenue increased to HK$118.07 million, driven by Tuoping Valsartan sales of HK$69.28 million; Tuoen Ibuprofen sales fell to HK$15.23 million.
• The board declared no interim dividend; management guided for a second-half commercial launch of Rosuvastatin Ezetimibe tablets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianda Pharmaceuticals Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260810-12279309), on August 10, 2026, and is solely responsible for the information contained therein.